Shanxi and China Biological Co-build Vaccine Joint Research and Development Center

Source: Medical Network

The Shanxi Provincial People's Government and China National Biotechnology Co., Ltd. (hereinafter referred to as "China Bio") signed a framework agreement to jointly build a vaccine joint research and development center and a vaccine clinical research base.

Wu Wei, vice governor of Shanxi Province, said that in the past five years, Shanxi has cooperated with China Biotech to carry out more than 10 vaccine phase III/IV clinical trials. The cooperation between the two parties to build a joint vaccine research and development center and a vaccine clinical research base is of great significance to promote the development and production of vaccines and specific drugs in Shanxi.

In recent years, China Biosciences has carried out 3 vaccine clinical projects in the Shanxi Provincial Center for Disease Control and Prevention. Among them, the quadrivalent influenza vaccine has passed the technical review of the drug regulatory department and the clinical and production site inspections; the quadrivalent meningococcal polysaccharide vaccine has been declared for production; the quadrivalent cervical cancer vaccine has completed the entire immunization process.

The Shanxi Provincial Center for Disease Control and Prevention is one of the earliest institutions in China to carry out vaccine clinical trials. China Biosciences is leading the country in terms of vaccine research and development, production, and distribution. This cooperation will focus on the inoculation, use, and clinical trials of human vaccines and other products. Effectiveness evaluation, epidemiological investigation, adverse reaction monitoring, and prevention and control of emerging and emerging infectious diseases will give full play to their respective advantages and develop together.

China's biological business scope covers six major biological product fields: human vaccines, blood products, medical beauty, animal health, antibody drugs, and medical diagnosis. Human vaccines can produce 50 kinds of vaccines annually, with an annual output of more than 700 million doses, providing more than 80% of the vaccines used in the national immunization program; the annual plasma collection volume exceeds 2,000 tons, and 11 blood products are being produced.

"Further strengthen exchanges and cooperation, and promote comprehensive cooperation between the two parties in various fields." Yang Xiaoming, chairman of China Biotech, said that through the construction of vaccine clinical research bases and vaccine joint research centers, we will focus on promoting the development of new vaccines and the transformation of scientific and technological achievements. Continue to increase investment in Shanxi.

China Biotech is responsible for the production and supply of more than 90% of Shanxi's immunization program vaccines, and has provided Shanxi with more than 200 million doses of various vaccines. "China Biological is willing to reorganize and acquire Shanxi Kangbao Biological Products Co., Ltd., and make additional investment to expand its blood product production capacity." Yang Xiaoming said that the overall investment is expected to exceed 1 billion yuan.

Wu Wei said that Shanxi is ready to carry out comprehensive, multi-field, and in-depth exchanges and cooperation under the framework agreement between the two parties. It will provide support in policy support, supporting investment, and talent guarantee to ensure that it includes the elderly over 60. Many beneficial cooperation projects including free inoculation of 23-valent pneumonia vaccine and emergency vaccination of new crown pneumonia vaccine have been implemented.